Drugs / GB241
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03003039 | Jun 2017 → May 2019 | B-cell non-Hodgkin lymphoma | Nanjing Yoko Biomedical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03650933 | Dec 2018 → Aug 2022 | diffuse large B-cell lymphoma | Nanjing Yoko Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB241 | “GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell...” NCT03650933 ↗ |
| Route | Intravenous | “GB241: 375 mg/m2, IV, day 1 of each cycle” NCT03650933 ↗ |